Skip to main content
IC
Pfizer Inc. (FRA:PFE)
Germany flag Germany · Delayed Price · Currency is EUR
20.50
-0.27 (-1.28%)
May 13, 2025, 7:36 PM CET

Revenue by Product

Fiscal year is January - December.
Fiscal Year
 FY 2024 FY 2023 FY 2022 FY 2021
Period Ending
 Dec '24 Dec '23 Dec '22 Dec '21
Oncology
Log In
Log In
Log In
Log In
Oncology Growth
Log In
Log In
Log In
Log In
Business Innovation (Pfizer CentreOne)
Log In
Log In
Log In
Log In
Business Innovation (Pfizer CentreOne) Growth
Log In
Log In
Log In
Log In
Global Pharmaceuticals Business (Biopharma)
Log In
Log In
Log In
Log In
Global Pharmaceuticals Business (Biopharma) Growth
Log In
Log In
Log In
Log In
Primary Care
Log In
Log In
Log In
Log In
Primary Care Growth
Log In
Log In
Log In
Log In
Specialty Care
Log In
Log In
Log In
Log In
Specialty Care Growth
Log In
Log In
Log In
Log In

Other

Fiscal year is January - December.
Fiscal Year
 FY 2024 FY 2023 FY 2022 FY 2021
Period Ending
 Dec '24 Dec '23 Dec '22 Dec '21
United States Revenue
Log In
Log In
Log In
Log In
United States Revenue Growth
Log In
Log In
Log In
Log In
Developed Europe Revenue
Log In
Log In
Log In
Log In
Developed Europe Revenue Growth
Log In
Log In
Log In
Log In
Developed Rest of World Revenue
Log In
Log In
Log In
Log In
Developed Rest of World Revenue Growth
Log In
Log In
Log In
Log In
Emerging Markets Revenue
Log In
Log In
Log In
Log In
Emerging Markets Revenue Growth
Log In
Log In
Log In
Log In
International Revenue
Log In
Log In
Log In
Log In
International Revenue Growth
Log In
Log In
Log In
Log In
Developed Markets Revenue
Log In
Log In
Log In
Log In
Developed Markets Revenue Growth
Log In
Log In
Log In
Log In
Emerging Markets Revenue (Post-FY2023 Reporting)
Log In
Log In
Log In
Log In
Emerging Markets Revenue (Post-FY2023 Reporting) Growth
Log In
Log In
Log In
Log In
Global Pharmaceuticals Business (Biopharma) Earnings
Log In
Log In
Log In
Log In
Global Pharmaceuticals Business (Biopharma) Earnings Growth
Log In
Log In
Log In
Log In
Other Business Activities Earnings
Log In
Log In
Log In
Log In
Other Business Activities Earnings Growth
Log In
Log In
Log In
Log In
Prevnar Revenue
Log In
Log In
Log In
Log In
Prevnar Revenue Growth
Log In
Log In
Log In
Log In
Xeljanz Revenue
Log In
Log In
Log In
Log In
Xeljanz Revenue Growth
Log In
Log In
Log In
Log In
Vaccines Revenue
Log In
Log In
Log In
Log In
Vaccines Revenue Growth
Log In
Log In
Log In
Log In
Ibrance Revenue
Log In
Log In
Log In
Log In
Ibrance Revenue Growth
Log In
Log In
Log In
Log In
Internal Medicine Revenue
Log In
Log In
Log In
Log In
Internal Medicine Revenue Growth
Log In
Log In
Log In
Log In
Inflammation & Immunology Revenue
Log In
Log In
Log In
Log In
Inflammation & Immunology Revenue Growth
Log In
Log In
Log In
Log In
Rare Disease Revenue
Log In
Log In
Log In
Log In
Rare Disease Revenue Growth
Log In
Log In
Log In
Log In
Eliquis Alliance Revenue and Direct Sales
Log In
Log In
Log In
Log In
Eliquis Alliance Revenue and Direct Sales Growth
Log In
Log In
Log In
Log In
Vyndaqel Family Revenue
Log In
Log In
Log In
Log In
Vyndaqel Family Revenue Growth
Log In
Log In
Log In
Log In
Hospital Revenue
Log In
Log In
Log In
Log In
Hospital Revenue Growth
Log In
Log In
Log In
Log In
Comirnaty Direct Sales and Alliance Revenue
Log In
Log In
Log In
Log In
Comirnaty Direct Sales and Alliance Revenue Growth
Log In
Log In
Log In
Log In
Paxlovid Revenue
Log In
Log In
Log In
Log In
Paxlovid Revenue Growth
Log In
Log In
Log In
Log In
Prevnar Family Revenue
Log In
Log In
Log In
Log In
Prevnar Family Revenue Growth
Log In
Log In
Log In
Log In
Nurtec ODT/Vydura Revenue
Log In
Log In
Log In
Log In
Nurtec ODT/Vydura Revenue Growth
Log In
Log In
Log In
Log In
Abrysvo Revenue
Log In
Log In
Log In
Log In
Abrysvo Revenue Growth
Log In
Log In
Log In
Log In